MDM2 SNP309 accelerates colorectal tumour formation in women

被引：75

作者：

Bond, Gareth L.

Menin, Chiara

Bertorelle, Roberta

Alhopuro, Pia

Aaltonen, Lauri A.

Levine, Arnold J.

机构：

[1] Inst Adv Study, Princeton, NJ 08540 USA

[2] Inst Canc Res, New Brunswick, NJ USA

[3] Biomed, Dept Med Genet, Helsinki, Finland

[4] Ist Oncol Veneta, Padua, Italy

来源：

JOURNAL OF MEDICAL GENETICS | 2006年 / 43卷 / 12期

关键词：

D O I：

10.1136/jmg.2006.043539

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Recent studies have shown that the G-allele of MDM2 SNP309 (T/G) in the p53 tumour suppressor pathway can accelerate tumorigenesis and alter the risk of various cancers in women and not in men. In this report, data are presented from two independent groups of patients that suggest that the G-allele of SNP309 accelerates colorectal tumour formation only in women, and that lend further support to the model that primarily female-specific hormones, such as oestrogen, could either directly or indirectly allow for the G-allele of SNP309 to accelerate tumour formation in women.

引用

页码：950 / 952

页数：3

共 10 条

[1] The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck [J].

Alhopuro, P ;

Ylisaukko-oja, SK ;

Koskinen, WJ ;

Bono, P ;

Arola, J ;

Järvinen, HJ ;

Mecklin, JP ;

Atula, T ;

Kontio, R ;

Mäkitie, AA ;

Suominen, S ;

Leivo, I ;

Vahteristo, P ;

Aaltonen, LM ;

Aaltonen, LA .

JOURNAL OF MEDICAL GENETICS, 2005, 42 (09) :694-698

[2] MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner [J].

Bond, Gareth L. ;

Hirshfield, Kim M. ;

Kirchhoff, Tomas ;

Alexe, Gabriella ;

Bond, Elisabeth E. ;

Robins, Harlan ;

Bartel, Frank ;

Taubert, Helge ;

Wuerl, Peter ;

Hait, William ;

Toppmeyer, Deborah ;

Offit, Kenneth ;

Levine, Arnold J. .

CANCER RESEARCH, 2006, 66 (10) :5104-5110

[3] MDM2 is a central node in the p53 pathway: 12 years and counting [J].

Bond, GL ;

Hu, WW ;

Levine, AJ .

CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :3-8

[4] A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].

Bond, GL ;

Hu, WW ;

Bond, EE ;

Robins, H ;

Lutzker, SG ;

Arva, NC ;

Bargonetti, J ;

Bartel, F ;

Taubert, H ;

Wuerl, P ;

Onel, K ;

Yip, L ;

Hwang, SJ ;

Strong, LC ;

Lozano, G ;

Levine, AJ .

CELL, 2004, 119 (05) :591-602

[5] p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population [J].

Jones, JS ;

Chi, XD ;

Gu, XJ ;

Lynch, PM ;

Amos, CI ;

Frazier, ML .

CLINICAL CANCER RESEARCH, 2004, 10 (17) :5845-5849

[6] The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC) [J].

Krüger, S ;

Bier, A ;

Engel, C ;

Mangold, E ;

Pagenstecher, C ;

Doeberitz, MV ;

Holinski-Feder, E ;

Moeslein, G ;

Schulmann, K ;

Plaschke, J ;

Rüschoff, J ;

Schackert, HK .

JOURNAL OF MEDICAL GENETICS, 2005, 42 (10) :769-773

[7] Improving cancer therapy by non-genotoxic activation of p53 [J].

Lain, S ;

Lane, D .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (08) :1053-1060

[8]

LIND H, 2006, INT J CANCER, V118, P1275

[9] Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status [J].

Menin, C ;

Scaini, MC ;

De Salvo, GL ;

Biscuola, M ;

Quaggio, A ;

Esposito, G ;

Belluco, C ;

Montagna, M ;

Agata, S ;

D'Andrea, E ;

Nitti, D ;

Amadori, A ;

Bertorelle, R .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (04) :285-288

[10] The IARC TP53 database: New Online mutation analysis and recommendations to users [J].

Olivier, M ;

Eeles, R ;

Hollstein, M ;

Khan, MA ;

Harris, CC ;

Hainaut, P .

HUMAN MUTATION, 2002, 19 (06) :607-614

← 1 →